Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
CAMBRIDGE, MASS. and TOKYO, JAPAN, February 14, 2014 – AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and...
SAN FRANCISCO, CA AND TOKYO, JAPAN – January 28, 2014 – Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced final results on the primary and secondary efficacy...
TOKYO, January 17, 2014 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced today that it has obtained the marketing approval of selective SGLT2...
Tokyo, January 15, 2014 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that the orally disintegrating tablet “Irribow® OD 1) Tablets...
Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585；Headquaters: Akita; CEO: Tatsuyoshi Hirano) today announced that the...
Tokyo, Japan; Rockville, MD; and Epalinges, Switzerland – January 6, 2014 – Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic...
Tokyo, December 25, 2013 - Astellas Pharma Inc. (“Astellas”) and Immuno-Biological Laboratories Co., Ltd. (“IBL”) today announced that they have concluded a collaborative research...
Tokyo, December 20, 2013 - Astellas Pharma Inc. (“Astellas”; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) announced the approval of an additional indication for hypnosedative,...
Read more about Approval of Additional Indication for Hypnosedative, Dormicum® in Japan
Tokyo, December 13, 2013 – Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka, hereinafter called “the Company”) announced that it completed acquisition of its...
Read more about Notice of Completion of Acquisition of Own Shares
Tokyo, December 13, 2013 - Astellas Pharma Inc. (“Astellas”; headquarters : Tokyo:4503; President and CEO: Yoshihiko Hatanaka), today announced that a definitive agreement has been concluded...
Tokyo and Boston, October 7, 2013 --- Astellas Pharma Inc. (Tokyo Stock Exchange: 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “Astellas”) and Mitokyne, Inc. (President and...
TOKYO, December 5, 2013 – On December 4, 2013, Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka), reached and entered into an agreement with Mitsui Fudosan...
Tokyo, November 15, 2013–Astellas Pharma Inc. (“Astellas,” Tokyo: 4503) and the Astellas Asia-Oceania Foundation* has pledged donations totaling US $70,000 to support victims of typhoon...
Read more about Support to Philippines Typhoon Haiyan and the Bohol Earthquake Relief Efforts
Tokyo, November 1, 2013 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) has signed an agreement with Accenture Japan Ltd. (headquarters: Tokyo, President:...
San Francisco, CA and Tokyo – October 22, 2013 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the Independent Data Monitoring Committee (IDMC) has...
Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585; Headquaters: Akita; CEO: Tatsuyoshi Hirano) today announced that the...
Tokyo, Japan, October 1, 2013 - Astellas Pharma Inc. (Tokyo: 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “Astellas”) established today Innovation Management (“AIM”), as...
Astellas Pharma Inc. (“Astellas”; headquarters : Tokyo:4503; President and CEO : Yoshihiko Hatanaka) today announced that a basic agreement has been concluded between Astellas Pharma Tech Co.,...
Follow us
